Why the study?
Does intracoronary nitric oxide (CAS-1609) improve postischemic coronary blood flow and myocardial contractile function in a canine model of myocardial ischemia-reperfusion?
Population
Canine model of myocardial ischemia-reperfusion
Comparison
CAS-1609, 1.25 mg iv 10 min before reperfusion… vs Saline vehicle
Design
Preclinical
Follow-up
4.5 hours
Authors
Loading...
Supports further study of nitric oxide donors in ischemia-reperfusion; leaves open translation from canine model to clinical practice.
Does intracoronary nitric oxide (CAS-1609) improve postischemic coronary blood flow and myocardial contractile function in a canine model of myocardial ischemia-reperfusion?
Intracoronary administration of a novel nitric oxide donor significantly augments postischemic coronary blood flow, improves contractile function, and reduces myocardial necrosis in a canine model of ischemia-reperfusion.
Pabla et al. (1995) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: